- 1 Brief Communication
- 2

Antigen Specific T Cells in People with Obesity at Five Months Following ChAdOx1 COVID-19 Vaccination

- 5
- 6 Neil E. Wrigley Kelly¹, Conor De Barra², Ferrah Shaamile³, Aisling Holland³, Liam Shaw¹, Patrick

7 W.G. Mallon⁴, Jean O'Connell³, Andrew E. Hogan^{2,5*} and Donal O'Shea^{1,3*}

- 8
- 9 Affiliation: ^{1.} St Vincent's University Hospital and University College Dublin, Dublin 4, Ireland.
- 10 ^{2.} Kathleen Lonsdale Institute for Human Health Research, Maynooth University, Maynooth,
- 11 Co Kildare, Ireland. ^{3.} St Columcille's Hospital, Loughlinstown, Co. Dublin, Ireland. ^{4.} Centre for
- 12 Experimental Pathogen Host Research, School of Medicine, University College Dublin, Ireland.
- ¹³ ^{5.} National Children's Research Centre, Dublin 12, Ireland. ^{*}Joint Senior Authors.
- 14
- 15 **Contact Information:**
- 16 Dr Andrew Hogan
- 17 Email: Andrew.E.Hogan@mu.ie
- 18 Address:
- 19 Biosciences Building,
- 20 Maynooth University, Maynooth,
- 21 Co. Kildare, Ireland.

22 Phone: +35317086118

23

24 Word Count: 1496

- 25
- 26 **Funding:** This work is supported by the National Children's Research Centre, a philanthropic
- 27 donation from the St Vincent's Foundation. Financial support for the Attune NxT was provided
- 28 to Maynooth University Department of biology by Science Foundation Ireland (16/RI/3399).
- 29
- 30 **Competing interests:** The authors declare no competing interests.
- 31

32 Abstract

Background/Objectives: People with obesity (PWO) face an increased risk of severe outcomes from COVID-19, including hospitalisation, ICU admission and death. Obesity has been seen to impair immune memory following vaccination against influenza, hepatitis B, tetanus, and rabies. Little is known regarding immune memory in PWO following COVID-19 adenovirus vector vaccination.

Subjects/Methods: We investigated SARS-CoV-2 specific T cell responses in 50 subjects, five
months following a two-dose primary course of ChAdOx1 nCoV-19 (AZD1222) vaccination.
We further divided our cohort into PWO (n=30) and matched controls (n=20). T cell (CD4⁺,
CD8⁺) cytokine responses (IFNγ, TNFα) to SARS-CoV-2 spike peptide pools were determined
using multicolour flow cytometry.

43 **Results:** Circulating T cells specific for SARS-CoV-2 were readily detected across our cohort, 44 with robust responses to spike peptide stimulation across both T cell lines. PWO and controls 45 had comparable levels of both CD4⁺ and CD8⁺ SARS-CoV-2 spike specific T cells. Polyfunctional 46 T cells – associated with enhanced protection against viral infection – were detected at similar 47 frequencies in both PWO and controls.

48 Conclusions: These data indicate that PWO who have completed a primary course of ChAdOx1
 49 COVID-19 vaccination have robust, durable, and functional antigen specific T cell immunity
 50 that is comparable to that seen in people without obesity.

51

52 Introduction

People with obesity (PWO) have a substantially increased risk of developing severe coronavirus disease 2019 (COVID-19). Many studies have summarised this relationship (1, 2). One meta-analysis for example outlined PWO to have a 113% increased risk of hospitalisation, 74% increased ICU admission and 48% higher mortality (1). The introduction of multiple highly efficacious COVID-19 vaccines mitigates the impact of the pandemic for many. This is of particular importance to those with obesity. However, little is known regarding immune memory following COVID-19 vaccination in this population.

60

PWO have impaired responses to vaccination in multiple settings. Impaired humoral responses have been observed following rabies (3), tetanus (4) and hepatitis B (5) immunisation. Furthermore, a study published in 2012 looked at PWO and controls without obesity following influenza vaccination, showing PWO to have both greater declines in antibody titres and lower frequencies of antigen specific CD8⁺ T cells at 12 months follow-up (6).

67

Antigen specific T cells have a crucial role in the adaptive response to SARS-CoV-2 infection and are protective against severe disease (7). They are durable, with longitudinal cohorts demonstrating their presence for at least 8 months post-vaccination (8). They are also more resilient to antigenic variation than antibody/B cell responses, as observed in the case of the omicron variant of concern (9).

73

The aim of this study was to evaluate if adults (18 years and older) with obesity (body mass index, BMI \ge 30.0 kg/m²) who have a history of COVID-19 adenovirus vector vaccination demonstrate poorer antigen specific T cell immunity compared to controls.

77

78 Materials/Subjects and Methods

79 We performed a cross-sectional cohort study looking at SARS-CoV-2 specific CD4⁺ and CD8⁺ 80 cell responses at 5 months following completion of a two-dose course of ChAdOx1 nCoV-19 81 (AZD1222) vaccine, with a dosing interval of 12 weeks. Subjects were recruited from staff 82 and outpatients attending the St. Columcille's Hospital, Loughlinstown COVID-19 vaccination 83 centre. 50 volunteers (30 PWO [BMI ≥30 kg/m²] and 20 controls [BMI <30 kg/m²]) were 84 included (see Table 1). Samples were collected over November and December 2021. 85 Inclusion criteria were: ability to give informed consent, age ≥18 years, 4 to 6 months since 86 second dose of ChAdOx1 nCoV-19 (AZD1222) vaccine. Exclusion criteria included: known 87 previous SARS-CoV-2 infection (confirmed by PCR or antigen test), treatment with certain 88 classes of immunosuppressants (anti-TNF agents, IL-1, IL-2, IL-6, IL-17 inhibitors) within the 89 preceding 8 months, obesity induced by other endocrine disorders, active 90 lymphoproliferative disorder and any active illness or medication which in the opinion of the 91 investigator precluded participation in the study. 92 93 Subjects were recruited as part of the Obesity Immunology Group cohort study. All subjects

provided written, informed consent. The study was conducted in accordance with the
 Declaration of Helsinki and ethical approval was granted by the St. Vincent's Hospital Group
 Research Ethics Committee.

97

98	Preparation of peripheral blood mononuclear cells (PBMC) and flow cytometric analysis
99	PBMCs were isolated from whole blood samples by centrifugation through density gradient
100	media (Lymphoprep™, Nycomed Pharma, Oslo, Norway), before suspension in cell
101	cryopreservation media and storage in a -70 °C freezer.
102	
103	Thawed PBMCs were stimulated with SARS-CoV-2 spike peptide pools (Miltenyi
104	PepTivator®SARS-CoV-2 research grade). After 4 hours protein transport inhibitor (Thermo
105	Fisher Scientific, Waltham, Massachusetts, USA) was added to each well, samples were
106	incubated at 37 °C for a further 12 hours. Having completed incubation, cells were
107	centrifuged, re-suspended in flow cytometry staining buffer, then stained for cell surface
108	markers (CD3, CD4, CD8). Following staining, live cells were fixed, permeabilised and
109	intracellular cytokine staining was performed. Multicolour flow cytometry was performed
110	using Attune™ NxT Flow Cytometer.
111	
112	Quantification and statistical analysis
113	Data and statistical analyses were performed using FlowJo v10.8.1 and GraphPad Prism 9
114	software. Statistical comparisons were performed using the Wilcoxon and Mann-Whitney U test,
115	where appropriate. Statistical significance for p values was <0.05. Background subtraction
116	was used when calculating antigen specific T cell frequencies.

117

118 **Results**

119 The clinical characteristics of the cohorts are presented in table 1.

120

121 **Robust SARS-CoV-2 specific T cell responses in people with obesity**

Adenovirus vector vaccines have been shown to elicit robust, durable SARS-CoV-2 specific T
cell responses following completion of vaccine course (8). We confirmed this to be the case
in our cohort, where both CD4⁺ and CD8⁺ cells were seen to express interferon gamma
(IFNγ) following stimulation with spike peptide pools (Figure 1A-C) (median CD8⁺ IFNγ⁺
frequency following spike stimulation: 0.780%, IQR 0.451-1.235%; median CD4⁺: 0.028%,
IQR 0.013-0.051%).

128

T cells that produce multiple cytokines are known as polyfunctional T cells. Their presence among the antigen specific T cell populations elicited by vaccination is highly desirable, as they are associated with enhanced protection against viral infections (10). Among our cohort polyfunctional T cells (IFNy⁺TNF α^+) were readily detectable across both conventional (CD4⁺ and CD8⁺) T cell lines following spike stimulation (Figure 1D-E) (median CD8⁺ IFNy⁺TNF α^+ frequency against spike: 0.463%, IQR 0.203-0.783%; median CD4⁺: 0.014%, IQR 0.008-0.031%).

136

Obesity has been associated with substantial innate and adaptive immune dysregulation, including impaired anti-viral immunity following infection or vaccination (6, 11). To investigate this, we separated our cohort into PWO and controls (median BMI 39.1 kg/m² [IQR 32.6-47.0] and 26 kg/m² [IQR 22.8-27.8]). PWO were seen to have robust SARS-CoV-2 specific T cell responses, with no differences in the frequencies of CD4⁺ and CD8⁺ T cells producing IFNy in response to spike stimulation (Figure 1F-G). Furthermore, similar frequencies of polyfunctional T cells were observed in those with and without obesity (Figure 1H-I).

144

145 **Discussion**

Given the greatly increased risk of severe COVID-19 in people with obesity it is important to properly characterise vaccine induced immunity in this vulnerable population. Here we studied antigen specific T cell responses in PWO and controls persisting to 5 months following a complete primary course of ChAdOx1 nCoV-19 (AZD1222) vaccine. Robust frequencies of antigen specific CD4⁺ and CD8⁺ T cells were identified across our cohort (n=50). Between group analysis provides evidence that SARS-CoV-2 specific T cell frequencies are preserved in PWO.

153

154 Specific forms of immunosuppression have been associated with impaired responses to 155 COVID-19 vaccines. These include people with haematological malignancies (12), solid organ 156 transplant recipients (13) and people with advanced HIV infection (14). Obesity has been 157 associated with extensive immune dysregulation, with chronic systemic inflammation and 158 loss of host protection (15). PWO have been seen to have impaired immune memory in 159 multiple settings. Weakened antibody responses have been seen following rabies (3), tetanus 160 (4) and hepatitis B vaccination (5). While impairment of both humoral and CD8⁺ T cell 161 responses has been seen following influenza vaccination (6).

162

Many questions remain regarding immune memory in PWO following COVID-19 vaccination. Most of the available evidence relates to the mRNA vaccines. The BNT162b2 vaccine has been associated with impairment of antibody responses in abdominal obesity (16). While followup of the phase III mRNA-1273 and BNT162b2 studies - at 5 and 6 months respectively showed very similar vaccine efficacy against symptomatic infection between people with and without obesity (17, 18). Regarding COVID-19 adenovirus vector vaccines, a study by Lee et al. showed antibody (IgG against receptor binding domain) responses to the ChAdOx1 nCoV-

170 19 vaccine to be unimpacted by elevated BMI (19). However, there are no published papers
171 describing antigen specific T cell responses in PWO following COVID-19 adenovirus vector
172 vaccination.

173

Our data demonstrate that PWO who have completed a two-dose course of ChAdOx1 nCoV-19 vaccine have robust antigen specific T cell responses along both CD8⁺ and CD4⁺ lines. Responses that are comparable in frequency to controls, as well as being comparable to the COVID-19 vaccine literature in general (8). The abundant presence of IFNγ expressing cells implies not just antigen recognition but functional capacity to inhibit viral replication and mobilise the immune response to infection. Polyfunctional T cells – readily detectable in PWO - have been seen to correlate with favourable disease evolution and protection (10).

181

182 As SARS-CoV-2 reaches a point of endemicity with primary vaccine courses, boosters, 183 infections, and not infrequent reinfections, it is important for us to understand the 184 implications of each antigenic exposure for vulnerable hosts. Physiological contraction of 185 peripheral antibody titres following infection (20) and vaccination (8), as well as viral antigenic 186 variation leading to immune escape diminish the protection conferred by humoral immunity. 187 This reinforces the importance of cellular (antigen specific T cell, memory B cell) immunity, 188 particularly in view of the evidence for conservation of T responses to the antigenic variation 189 thus far observed in variants of concern (9).

190

Our study has limitations. While the groups in this study were well matched for age and
 mean days from second vaccine dose, they were less well matched for sex. Future research
 regarding immune memory in PWO in COVID-19 is critical. As the pandemic progresses,

194 longitudinal studies are required in order to continue to characterise the longevity of

cellular and humoral responses in this population, as well as to define precise correlates ofprotection.

197

198	In summary, we measured SARS-CoV-2 specific CD4 ⁺ and CD8 ⁺ cell responses in people with
199	obesity following ChAdOx1 COVID-19 vaccination, showing features associated with
200	protective immunity and providing evidence that antigen specific T cell frequencies are not
201	impacted by obesity.
202	
203	Acknowledgements: The authors wish to thank all study participants and their families. We
204	would like to thank Prof. Alan Landay and Prof. Michael Turner, for their expert input and
205	support. We wish to acknowledge the Irish Coalition for People Living with Obesity (ICPO) for
206	their important advocacy work.
207	
208	Author Contributions: NEWK optimized the experimental protocol and performed the
209	experiments. CDB provided technical assistance. NEWK, FS, AH, LS, JOC and DOS recruited
210	study participants. NEWK processed and biobanked samples. NEWK, JOC and DOS analysed
211	the clinical cohorts. NEWK and AEH analysed the data and drafted the manuscript. AEH,
212	DOS, JOC, PM and NEWK conceptualized/designed the study and approved the final
213	manuscript as submitted.
214	
215	Competing interests: The authors declare no competing interests.

Data availability statement: The datasets generated during and/or analysed during the

218 current study are available from the corresponding author on reasonable request.

220 221 222	References		
	1. Popkin BM, Du S, Green WD, Beck MA, Algaith T, Herbst CH, et al. Individuals with		
223	obesity and COVID-19: A global perspective on the epidemiology and biological relationships.		
224	Obes Rev. 2020;21(11):e13128.		
225	2. Gao M, Piernas C, Astbury NM, Hippisley-Cox J, O'Rahilly S, Aveyard P, et al.		
226	Associations between body-mass index and COVID-19 severity in 6.9 million people in		
227	England: a prospective, community-based, cohort study. The Lancet Diabetes &		
228	Endocrinology. 2021;9(6):350-9.		
229	3. Banga N, Guss P, Banga A, Rosenman KD. Incidence and variables associated with		
230	inadequate antibody titers after pre-exposure rabies vaccination among veterinary medical		
231	students. Vaccine. 2014;32(8):979-83.		
232	4. Eliakim A, Schwindt C, Zaldivar F, Casali P, Cooper DM. Reduced tetanus antibody		
233	titers in overweight children. Autoimmunity. 2006;39(2):137-41.		
234	5. Weber DJ, Rutala WA, Samsa GP, Bradshaw SE, Lemon SM. Impaired		
235	immunogenicity of hepatitis B vaccine in obese persons. N Engl J Med. 1986;314(21):1393.		
236	6. Sheridan PA, Paich HA, Handy J, Karlsson EA, Hudgens MG, Sammon AB, et al.		
237	Obesity is associated with impaired immune response to influenza vaccination in humans. In		
238	J Obes (Lond). 2012;36(8):1072-7.		
239	7. Moderbacher CR, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al.		
240	Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations		
241	with age and disease severity. Cell. 2020.		

Collier AY, Yu J, McMahan K, Liu J, Chandrashekar A, Maron JS, et al. Differential
 Kinetics of Immune Responses Elicited by Covid-19 Vaccines. N Engl J Med.
 2021;385(21):2010-2.

245 9. Tarke A, Coelho CH, Zhang Z, Dan JM, Yu ED, Methot N, et al. SARS-CoV-2
246 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha
247 to Omicron. Cell. 2022;185(5):847-59 e11.

248 10. Goncalves Pereira MH, Figueiredo MM, Queiroz CP, Magalhaes TVB, Mafra A, Diniz
249 LMO, et al. T-cells producing multiple combinations of IFNgamma, TNF and IL10 are
250 associated with mild forms of dengue infection. Immunology. 2020;160(1):90-102.

11. O'Shea D, Corrigan M, Dunne MR, Jackson R, Woods C, Gaoatswe G, et al. Changes
in human dendritic cell number and function in severe obesity may contribute to increased
susceptibility to viral infection. Int J Obes (Lond). 2013;37(11):1510-3.

12. Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, et al.
Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer
Cell. 2021;39(8):1081-90 e2.

257 13. Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, et al.

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant
 Recipients. JAMA. 2021;325(21):2204-6.

14. Hassold N, Brichler S, Ouedraogo E, Leclerc D, Carroue S, Gater Y, et al. Impaired
antibody response to COVID-19 vaccination in advanced HIV infection. AIDS.
2022;36(4):F1-F5.

263 15. Green WD, Beck MA. Obesity Impairs the Adaptive Immune Response to Influenza
264 Virus. Ann Am Thorac Soc. 2017;14(Supplement_5):S406-S9.

16. Watanabe M, Balena A, Tuccinardi D, Tozzi R, Risi R, Masi D, et al. Central obesity,
smoking habit, and hypertension are associated with lower antibody titres in response to
COVID-19 mRNA vaccine. Diabetes Metab Res Rev. 2022;38(1):e3465.

17. Thomas SJ, Moreira ED, Jr., Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety
and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med.
2021;385(19):1761-73.

18. El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, et al.

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J
Med. 2021;385(19):1774-85.

19. Lee SW, Moon JY, Lee SK, Lee H, Moon S, Chung SJ, et al. Anti-SARS-CoV-2 Spike

275 Protein RBD Antibody Levels After Receiving a Second Dose of ChAdOx1 nCov-19

276 (AZD1222) Vaccine in Healthcare Workers: Lack of Association With Age, Sex, Obesity, and

Adverse Reactions. Front Immunol. 2021;12:779212.

278 20. Mallon PWG, Tinago W, Leon AG, McCann K, Kenny G, McGettrick P, et al.

279 Dynamic Change and Clinical Relevance of Postinfectious SARS-CoV-2 Antibody Responses.

280 Open Forum Infect Dis. 2021;8(8):ofab122.

281

282 283

-00

Figure 1. SARS-CoV-2 spike specific T cell responses of subjects at 5 months following
 ChAdOx1 COVID-19 vaccination.

286 (A) Representative flow cytometry gating strategy for detection of T cell subsets (CD8⁺ or 287 CD4⁺) and their cytokine production. (B-E) Scatter plot showing the frequencies of cytokine 288 expressing T cells (CD8⁺ or CD4⁺) from vaccinated individuals following overnight stimulation 289 with SARS-CoV-2 spike peptide pools. (F-I) Frequencies of T cell subsets (CD8⁺ or CD4⁺) in 290 COVID-19 vaccinated individuals with (PWO) or without obesity (controls), producing cytokine 291 $(TNF\alpha, IFN\gamma)$ in response to overnight stimulation with SARS-CoV-2 spike peptide pools. 292 Where bars are present they denote median. Statistical comparisons across cohorts were 293 performed with the Wilcoxon test for paired data (B-E) and Mann-Whitney U test for unpaired 294 data (F-I). Data for (F-I) were background subtracted against negative control.









Figure 1

Table 1: Participant Characteristics					
	People with Obesity	Controls			
Total number (%)	30 (60)	20 (40)			
Age (years)	60.5 (47.5-67.0)	63.0 (60.3-65.0)			
BMI (kg/m²)	39.1 (32.6-47.0)	26 (22.8-27.8)			
Female (n [%])	18 (60)	8 (40)			
Days from second vaccine dose	158 (153-166)	154 (152-158)			
Data are median (IQR) unless specified. BMI: body mass index.					